A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
← catalyst calendarNCT07088926 · readout in 477 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
435estimated
Sites
187
Countries
Argentina, Australia, Belgium +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-06 | actual | When the study began enrolling |
| Primary completion | 2027-12-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bronchiectasis With Pseudomonas Aeruginosa Colonization
Interventions
- Biological: AZD0292
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of exacerbations over a variable follow-up time
measured Min 28 weeks, max 52 weeks
Publications
- PMID 29386336 — cited as background
- PMID 31931782 — cited as background
- PMID 27692133 — cited as background
- PMID 24328736 — cited as background
- PMID 25792635 — cited as background
- PMID 30442957 — cited as background
- PMID 29357265 — cited as background
- PMID 29478908 — cited as background
- PMID 25722615 — cited as background
- PMID 33401148 — cited as background
- PMID 39322263 — cited as background
- PMID 31130925 — cited as background
- PMID 22734046 — cited as background
- PMID 12112774 — cited as background
- PMID 13823475 — cited as background
- PMID 31613151 — cited as background
- PMID 35125294 — cited as background
- PMID 39293722 — cited as background
- PMID 28596426 — cited as background
- PMID 31462403 — cited as background
- PMID 1759018 — cited as background
- PMID 31405826 — cited as background
- PMID 38754132 — cited as background
- PMID 39384303 — cited as background
- PMID 35947710 — cited as background
- PMID 17493497 — cited as background
- PMID 22743675 — cited as background
- PMID 24626872 — cited as background
- PMID 25323621 — cited as background
- PMID 16461139 — cited as background
- PMID 31109172 — cited as background
- PMID 39274224 — cited as background
- PMID 30016475 — cited as background
- PMID 37031164 — cited as background
- PMID 27492530 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed